4.7 Article

Salvage Treatment Using Carbon Ion Radiation in Patients With Locoregionally Recurrent Nasopharyngeal Carcinoma: Initial Results

Journal

CANCER
Volume 124, Issue 11, Pages 2427-2437

Publisher

WILEY
DOI: 10.1002/cncr.31318

Keywords

intensity-modulated carbon ion radiotherapy; recurrent nasopharyngeal carcinoma; reirradiation; survival; toxicity

Categories

Funding

  1. National Key Research and Development Program of China [2017YFC0108603]
  2. Joint Breakthrough Project for New Frontier Technologies of the Shanghai Hospital Development Center [SHDC 12015118]
  3. Science and Technology Commission of Shanghai Municipality [15411950102, 15411950106]

Ask authors/readers for more resources

BACKGROUND: Reirradiation for locoregionally recurrent nasopharyngeal carcinoma (NPC) after a definitive dose of radiotherapy (RT) is challenging and usually associated with severe toxicities. Intensity-modulated carbon ion RT (IMCT) offers physical/biologic advantages over photon-based intensity-modulated RT. Herein, the authors report their initial experience of IMCT in previously irradiated patients with locoregionally recurrent NPC. METHODS: Patients with locoregionally recurrent, poorly differentiated or undifferentiated NPC who underwent salvage therapy with IMCT at the Shanghai Proton and Heavy Ion Center between May 2015 and August 2017 were included in the current study. The IMCT doses were 50 to 66 Gray equivalent (GyE) (2.0-3.0 GyE/daily fraction), delivered via raster scanning technology. The 1-year overall survival, disease-specific survival, progression-free survival (PFS), local recurrence-free survival, regional recurrence-free survival, and distant metastasis-free survival were calculated. Univariate and multivariate analyses of PFS were performed to identify possible predictive factors. RESULTS: Among the 75 patients included, 4 patients, 14 patients, 29 patients, and 28 patients, respectively, had recurrent American Joint Committee on Cancer stage I, stage II, stage III, and stage IVA/B disease. With a median follow-up of 15.4 months (range, 2.6-29.7 months), the 1-year overall survival, disease-specific survival, PFS, local recurrence-free survival, regional recurrence-free survival, and distant metastasis-free survival rates were 98.1%, 98.1%, 82.2%, 86.6%, 97.9%, and 96.2%, respectively. A higher fraction size of 3 GyE (vs <3 GyE) or a higher biological equivalent dose significantly improved the PFS rate on univariate analysis, but not on multivariate analysis. No patient developed acute toxicity of grade 2 during IMCT. Late treatment-induced severe (grade 3 or 4) toxicities were infrequent, but included mucosal necrosis (9.3%), xerostomia (1.3%), and temporal lobe necrosis (1.3%). CONCLUSIONS: This initial experience in the first 75 patients with locoregionally recurrent NPC was encouraging. Carbon ion RT could provide promising survival rates with infrequent severe toxicities for patients with locoregionally recurrent NPC. (C) 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

VMP1, a novel prognostic biomarker, contributes to glioma development by regulating autophagy

Wanzun Lin, Yun Sun, Xianxin Qiu, Qingting Huang, Lin Kong, Jiade J. Lu

Summary: The study found that high expression of VMP1 in glioma patients is associated with faster disease progression and poorer prognosis. Depletion of VMP1 by CRISPR-Cas9 gene editing significantly inhibits cell proliferation, increases cell death, and induces cell cycle arrest. Knockout of VMP1 blocks autophagic flux and sensitizes glioma cells to radiotherapy and chemotherapy.

JOURNAL OF NEUROINFLAMMATION (2021)

Article Oncology

Mixed Photon and Carbon-Ion Beam Radiotherapy in the Management of Non-Metastatic Nasopharyngeal Carcinoma

Jiyi Hu, Qingting Huang, Jing Gao, Weixu Hu, Jing Yang, Xiyin Guan, Xianxin Qiu, Wenna Zhang, Lin Kong, Jiade J. Lu

Summary: The study demonstrated that the combination of IMRT with CIRT boost therapy provides excellent disease control and favorable toxicity profile for patients with non-metastatic nasopharyngeal carcinoma. The results suggest that this mixed treatment strategy is safe and well-tolerated, with promising outcomes in terms of disease control.

FRONTIERS IN ONCOLOGY (2021)

Article Radiology, Nuclear Medicine & Medical Imaging

Adaptive carbon ion radiotherapy for locally advanced non-small cell lung cancer: Organ-sparing potential and target coverage

Shubing Jia, Jian Chen, Ningyi Ma, Jingfang Zhao, Jingfang Mao, Guoliang Jiang, Jiade Lu, Kailiang Wu

Summary: This study demonstrates the dosimetric benefits of adaptive carbon ion radiotherapy (CIRT) for locally advanced non-small cell lung cancer (LANSCLC) and compares the differences between patients with and without adaptive plans. The results show that adaptive plans can ensure target coverage and reduce spinal cord dose. Patients with adaptive plans have larger tumor volumes and greater volume changes. iGTV volume changes and iGTV center movements are the main factors influencing adaptive planning.

MEDICAL PHYSICS (2022)

Article Oncology

Mesenchymal Stem Cells Inhibits Migration and Vasculogenic Mimicry in Nasopharyngeal Carcinoma Via Exosomal MiR-125a

Fangzhu Wan, Haojiong Zhang, Jiyi Hu, Li Chen, Shikai Geng, Lin Kong, Jiade J. Lu

Summary: This study identified miR-125a as highly expressed in normal nasopharyngeal epithelial tissue compared to nasopharyngeal carcinoma. It demonstrated that miR-125a inhibits the migration and vasculogenic mimicry (VM) formation in nasopharyngeal carcinoma cells, targeting TAZ. Additionally, artificial engineering of mesenchymal stem cells (MSCs) allowed the generation of miR-125a-overexpressing exosomes which attenuated VM formation and migration in nasopharyngeal carcinoma, providing a potential therapeutic approach.

FRONTIERS IN ONCOLOGY (2022)

Article Ophthalmology

One-Year Efficacy and Safety of Proton-Beam Irradiation Combined with Intravitreal Conbercept for Refractory or Recurrent Polypoidal Choroidal Vasculopathy: A Pilot Study

Jingli Guo, Xianxin Qiu, Wenyi Tang, Gezhi Xu, Michael F. Moyers, Wei Ren, Ying Xing, Jin Gao, Jiayao Sun, Jiade Lu, Lin Kong, Wei Liu

Summary: The study demonstrates that PBI combined with IVC may help promote regression and closure of polyps in PCV, reduce central macular thickness, and improve BCVA with good safety profile after 12 months. Hence, PBI may be a useful adjuvant therapy for patients with refractory or recurrent PCV.

OPHTHALMOLOGY AND THERAPY (2022)

Article Oncology

Feasibility of lattice radiotherapy using proton and carbon-ion pencil beam for sinonasal malignancy

Dong Yang, Weiwei Wang, Jiyi Hu, Weixu Hu, Xiyu Zhang, Xiaodong Wu, Jiade J. Lu, Lin Kong

Summary: This study investigated the feasibility of lattice radiotherapy (LRT) using proton or carbon-ion beams in the treatment of sinonasal malignancies. The results showed that proton and carbon-ion LRT plans can better protect critical organs compared to photon LRT plans, despite minimal differences in PVDR.

ANNALS OF TRANSLATIONAL MEDICINE (2022)

Article Oncology

The Majority of United States Citizens With Cancer do not Have Access to Carbon Ion Radiotherapy

Robert L. Foote, Hirohiko Tsujii, Reiko Imai, Hiroshi Tsuji, Eugen B. Hug, Tatsuaki Kanai, Jiade J. Lu, Juergen Debus, Rita Engenhart-Cabillic, Anita Mahajan

Summary: As of December 31, 2020, there were 12 facilities in Asia and Europe providing carbon ion radiotherapy (CIRT) for cancer patients, with a total of 37,548 patients treated worldwide. The absence of CIRT facilities in the U.S. limits access to this treatment for American cancer patients and prevents their inclusion in phase III clinical trials, which are essential for FDA approval and insurance coverage. Overcoming this barrier would require establishing a limited number of CIRT facilities in the U.S.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

METTL3-mediated m6A mRNA contributes to the resistance of carbon-ion radiotherapy in non-small-cell lung cancer

Xiaofeng Xu, Peiru Zhang, Yangle Huang, Weizhong Shi, Jingfang Mao, Ningyi Ma, Lin Kong, Lin Guo, Jinlong Liu, Jian Chen, Renquan Lu

Summary: This study found that the levels of METTL3 and its mediated m6A modification were elevated in non-small-cell lung cancer (NSCLC) cells treated with carbon-ion radiotherapy. Knockdown of METTL3 impaired cell proliferation, migration, invasion, and enhanced DNA damage repair and cell survival.

CANCER SCIENCE (2023)

Article Cell Biology

Carbon Ion Irradiation Downregulates Notch Signaling in Glioma Cell Lines, Impacting Cell Migration and Spheroid Formation

Vivek Kumar, Mohit Vashishta, Lin Kong, Jiade J. Lu, Xiaodong Wu, Bilikere S. Dwarakanath, Chandan Guha

Summary: Photon-based radiotherapy and carbon ion radiotherapy have different effects on Notch signaling in glioma cells. Carbon ion radiotherapy regulates the expression of Notch signaling and reduces stemness and cell migration. These findings may contribute to reducing tumor regrowth and disease dissemination.

CELLS (2022)

Article Cell Biology

Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma

Qilin Zhang, Lijiang Fei, Rui Han, Ruofan Huang, Yongfei Wang, Hong Chen, Boyuan Yao, Nidan Qiao, Zhe Wang, Zengyi Ma, Zhao Ye, Yichao Zhang, Weiwei Wang, Ye Wang, Lin Kong, Xuefei Shou, Xiaoyun Cao, Xiang Zhou, Ming Shen, Haixia Cheng, Zhenwei Yao, Chao Zhang, Guoji Guo, Yao Zhao

Summary: By performing single-cell RNA sequencing, we revealed the cellular hierarchies of skull base chordoma (SBC) and identified potential targets and drugs for the treatment of SBC.

CELL DISCOVERY (2022)

Article Immunology

Identification of molecular subtypes based on inflammatory response in lower-grade glioma

Wanzun Lin, Jing Gao, Haojiong Zhang, Li Chen, Xianxin Qiu, Qingting Huang, Jiyi Hu, Lin Kong, Jiade J. Lu

Summary: This study classified lower-grade glioma (LGG) into inflammation-, low, -mid, and -high subtypes based on the inflammatory response, which have distinct clinicopathologic features, prognosis, and tumor microenvironment. An inflammation-related prognostic model was also established with strong predictive power for prognosis assessment.

INFLAMMATION AND REGENERATION (2022)

No Data Available